revamilast
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01430507)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12- Mol. weight
- 440.19 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297527 ↗
Also known as
- revamilast
- revamilast
- revamilast
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01436890 | Phase 2 | Oct 1, 2011 | Glenmark Pharmaceuticals |
| NCT01430507 | Phase 2 | Sep 1, 2011 | Glenmark Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glenmark Pharmaceuticals | For profit | 2 | 2 | 1 | 2011 |
1 organizations
Page 1 / 1